Corcept Therapeutics Incorporated (CORT)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 107,282 | 112,634 | 124,477 | 128,202 | 111,606 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 506,705 | 501,842 | 375,806 | 523,338 | 371,182 |
| Return on total capital | 21.17% | 22.44% | 33.12% | 24.50% | 30.07% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $107,282K ÷ ($—K + $506,705K)
= 21.17%
Corcept Therapeutics Inc's return on total capital has shown variations over the past five years, ranging from 21.17% to 33.12%. The return on total capital decreased from 33.12% in 2021 to 21.17% in 2023, indicating a decline in the company's ability to generate returns from both equity and debt capital. However, it is noteworthy that even at 21.17% in 2023, the return on total capital remains relatively stable compared to 2020 and 2019.
The fluctuations in return on total capital may be attributed to changes in the company's operational efficiency, profitability, capital structure, and overall financial performance. It is essential for investors and stakeholders to closely monitor these trends to assess the company's financial health and sustainability in the long term.
Peer comparison
Dec 31, 2023